Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The companys six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Venture Financing 17
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
Private Equity 19
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Partnerships 20
Replimune Enters into Co-Development Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Agreement with Alnylam Pharma 21
Regeneron Pharma and ISA Pharma Enter into Partnership 22
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 23
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 24
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 25
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 26
Inovio Pharma and Regeneron Pharma Enter into Agreement 27
Indivumed Enters into Agreement with Regeneron Pharma 28
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 29
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 31
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 32
Bayer Enters into Co-Development Agreement with Regeneron Pharma 33
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 34
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 35
Regeneron Pharma Enters into Development Agreement with BARDA 36
Regeneron Pharma Amends Co-Development Agreement with Sanofi 37
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 40
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 41
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 42
Licensing Agreements 44
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 44
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 45
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 46
Regeneron Pharma Enters into Licensing Agreement with MedImmune 48
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 49
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 50
Regeneron Pharmaceuticals Inc - Key Competitors 51
Regeneron Pharmaceuticals Inc - Key Employees 52
Regeneron Pharmaceuticals Inc - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 55
Financial Announcements 55
May 03, 2018: Regeneron Reports First Quarter 2018 Financial And Operating Results 55
Feb 08, 2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results 58
Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 61
Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 64
May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 67
Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 70
Corporate Communications 74
Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial 74
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 75
Legal and Regulatory 76
Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regenerons Petition to Rehear the Panels Decision Affirming Merus Inequitable Conduct Claim Against Regeneron 76
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus Inequitable Conduct Claim Against Regeneron 77
Government and Public Interest 78
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 78
Mar 13, 2018: Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease 80
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on Worlds Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 82
Product News 84
09/08/2017: Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma 84
08/17/2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis 85
05/31/2018: Regenerons Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak 86
04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 87
02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 88
01/13/2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 89
Clinical Trials 90
Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology 90
Dec 13, 2017: Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma 91
Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program 92
Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 93
Nov 01, 2017: Regeneron to Share Clinical Progress of Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting 95
Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 96
Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 98
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 100
Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 102
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 103
Other Significant Developments 105
May 18, 2018: Experimental MERS Treatments Enter Clinical Trial 105
Appendix 106
Methodology 106
About GlobalData 106
Contact Us 106
Disclaimer 106

List Of Tables

List of Tables
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Replimune Enters into Co-Development Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Agreement with Alnylam Pharma 21
Regeneron Pharma and ISA Pharma Enter into Partnership 22
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 23
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 24
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 25
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 26
Inovio Pharma and Regeneron Pharma Enter into Agreement 27
Indivumed Enters into Agreement with Regeneron Pharma 28
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 29
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 31
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 32
Bayer Enters into Co-Development Agreement with Regeneron Pharma 33
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 34
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 35
Regeneron Pharma Enters into Development Agreement with BARDA 36
Regeneron Pharma Amends Co-Development Agreement with Sanofi 37
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 40
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 41
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 42
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 44
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 45
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 46
Regeneron Pharma Enters into Licensing Agreement with MedImmune 48
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 49
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 50
Regeneron Pharmaceuticals Inc, Key Competitors 51
Regeneron Pharmaceuticals Inc, Key Employees 52
Regeneron Pharmaceuticals Inc, Other Locations 54
Regeneron Pharmaceuticals Inc, Subsidiaries 54

List Of Figures

List of Figures
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Regeneron: Performance, Capabilities, Goals and Strategies in the Global Biotechnology Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The companys six US FDA-approved medicines and product

USD 250 View Report

Pivot Pharmaceuticals Inc (PVOTF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pivot Pharmaceuticals Inc (Pivot Pharmaceuticals), formerly Neurokine Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of cannabinoid based neutraceutical and pharmaceutical products. The companys major

USD 250 View Report

Fog Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fog Pharmaceuticals Inc (Fog Pharmaceuticals) is a clinical-stage biotechnology company that discovers and develops next-generation peptide inhibitors that target traditionally undruggable intracellular protein-protein interactions. The company develops cell-penetrating miniproteins (CPMPs),

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available